TrialBreast cancer research : BCR2026

The ARTEMIS trial identifies immune activation as a key predictor of neoadjuvant chemotherapy response in triple-negative breast cancer.

Sahil Seth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.